Filing Details
- Accession Number:
- 0001628280-23-042631
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-22 16:04:30
- Reporting Period:
- 2023-12-22
- Accepted Time:
- 2023-12-22 16:04:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1104506 | Insmed Inc | INSM | Pharmaceutical Preparations (2834) | 541972729 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1796960 | M.d. Martina Flammer | 700 Us Highway 202/206 Bridgewater NJ 08807 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-12-22 | 28,310 | $23.66 | 134,348 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-12-22 | 28,310 | $30.00 | 106,038 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2023-12-22 | 28,310 | $0.00 | 28,310 | $23.66 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
122,680 | 2030-01-02 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- In connection with the appointment of Dr. Flammer as the Company's Chief Medical Officer, the Company granted Dr. Flammer an option to purchase a total of 150,990 shares of the Company's common stock. The option becomes exercisable based on the following vesting schedule: twenty-five percent (25%) vest on the first anniversary of the date of grant and twelve and one-half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Dr. Flammer's continued employment with the Company on each vesting date.